Premium
EFFECT OF METOCLOPRAMIDE ON PLASMA VASOPRESSIN IN MAN
Author(s) -
NOMURA K.,
KURIMOTO F.,
DEMURA H.,
SAKURAI H.,
NOMURA T.,
ZIBIKI K.,
NARUSE M.,
KANAI N.,
SHIZUME K.
Publication year - 1984
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1984.tb03450.x
Subject(s) - metoclopramide , vasopressin , endocrinology , medicine , chemistry , vomiting
SUMMARY The effect of metoclopramide, a dopamine blocker, on arginine vasopressin (AVP) secretion was investigated in normal males. After a bolus injection of metoclopramide (10 mg), all subjects ( n = 7) demonstrated an increase of 80‐3% (from 0.71 ±0.12 (Mean ± S.E.) to 1.28 ± 0.24 pg/ml, P ± 0005) in plasma AVP at 15 min. In controls ( n = 7) plasma AVP levels did not change after saline injection (2 ml). Because plasma osmolality and blood pressure did not change, the elevation of plasma AVP levels induced by treatment with metoclopramide may be due to its central effect as a dopamine inhibitor. Although plasma AVP levels increased again at 90 and 120 min after a bolus injection of metoclopramide, accompanying falls in blood pressure (4‐5%) make the interpretation concerning the contribution of dopamine to AVP secretion in a late phase uncertain. In summary, plasma AVP levels were shown to be significantly increased by a metoclopramide bolus, suggesting that AVP secretion is under tonic inhibition by dopamine.